Skip Navigation
Search Menu

Print This Page
Share this page: More


Cancer is very complex. It is a disease of many broken parts and in order to fix these parts, researchers need to understand them in detail. Groundbreaking discoveries led by scientists at the Johns Hopkins Kimmel Cancer Center found that breast cancer is not just one disease but a number of diseases. Several breast cancers might look alike under the microscope, but genetically they are very different. Most breast cancers are caused by a series of changes in normal cells acquired over time. These cellular alterations are red flags or biomarkers which can identify those at risk and can serve as targets for prevention.

Johns Hopkins has led the world in deciphering the cellular causes of cancer. Now our internationally-recognized team of Johns Hopkins breast cancer physician-scientists, lead by Vered Stearns, M.D., and Sara Sukumar, Ph.D., is poised to lead in the prevention of cancer. The Johns Hopkins Kimmel Cancer Center is one of the few centers in the country where significant collaboration occurs across departments and schools within the University system. Researchers in the Bloomberg School of Hygiene and Public Health identify and decipher risk factors for breast cancer while laboratory scientists in the School of Medicine describe the biological basis for breast cancer development. When these groups collaborate risk factors identified by our public health scientists can be investigated so that we understand their biological basis; biomarkers identified by our laboratory scientists can be the next generation of risk factors used by our public health scientists to identify groups at risk.

Breast Cancer Vaccine

Dr. Leisha Emens is working on the development of novel therapeutic cancer vaccines for breast cancer treatment and prevention that teach the dendritic cells to recognize that tumor cells are different from normal cells and thus need to be attacked and destroyed. Using the vaccine in combination with chemotherapy enhances the vaccine’s ability to excite the immune system against cancer. In clinical trials she has been testing a vaccine composed of breast cancer cells genetically modified to secrete the immune-stimulating hormone granulocyte-macrophage colony-stimulating factor (GM-CSF). The vaccine incites a response that re-stimulates the immune system to seek out and destroy microscopic breast cancer cells and premalignant cells.

In 2009, Dr. Emens and colleagues reported the results from a phase I trial of the vaccine in combination with low doses of the chemotherapy drugs cyclophosphamide and doxorubicin in 28 patients with metastatic breast cancer. The work, published in the Journal of Clinical Oncology, showed that the drugs induced a higher level of immunity from the vaccine.

Results from a phase II trial testing the vaccine in combination with cyclophosphamide and weekly trastuzumab (Herceptin) therapy for patients with metastatic breast cancer are being submitted for publication. Additional trials still recruiting patients will evaluate the vaccine’s effectiveness with and without Herceptin for patients with metastatic breast cancer, and will study the side effects of giving Herceptin together with cyclophosphamide and the vaccine in patients with high-risk or metastatic breast cancer.

Dr. Richard Zellars and colleagues are actively pursuing a number of clinical trials designed to improve radiation therapy and its outcomes. One is studying the safety of combined radiation and chemotherapy in which women receive three weeks’ of radiation therapy overlapping with their first two cycles of chemotherapy. This takes the average time of treatment of chemotherapy followed by radiation from an average of six months down to less than two months.

In the trial, women receive partial breast irradiation that lasts daily for three weeks compared to seven. Because a smaller area of tissue receives the radiation, a larger dose can be given each day --- allowing patients to receive the same effective dose of radiation in a shorter period of time. Chemotherapy is given once every two weeks and is started at the same time that radiation begins. The bi-monthly chemotherapy lasts an extra 4 weeks after the radiation ends. In addition to shortening the duration of daily radiation treatments in the combined approach, the investigators believe that the radiation may make the breast cancer cells more sensitive (and more likely to be killed) by the chemotherapy. Results of a study of 25 women published in the Journal of Clinical Oncology in 2009 showed that the patients’ side effects were lessened with the combined therapy. A study in a larger number of women is now underway.

Another trial is studying proteins in the blood of breast cancer patients. Blood samples taken from women undergoing radiation after lumpectomy are being studied to see if certain proteins may predict which patients may experience side effects from radiation.

Read more about radiation oncology.

Read an article about Dr. Zellars’ work, featured in the Winter 2009 issue of the Hopkins newsletter On Target.

Epigenetic Therapy

A new clinical trial is available for patients with advanced or metastatic breast cancer.  The trial will test two drugs that target specific changes in cancer cells.  Study sites, including Johns Hopkins and other institutions in six states in the Unites States. Call 410-955-8804 for information.

Intraductal Therapy

Drs. Sara Sukumar and Vered Stearns, co-directors of the Breast Cancer Program, have been studying this potential treatment to deliver anti-cancer drugs through a tiny catheter inserted in the nipple directly to epithelial cells lining the breast ducts. This could save the breast and spare the rest of the body from side effects.  “If you get rid of the epithelial cells,” Dr. Sukumar says, “you get rid of the cancer-causing cells while leaving the breast itself intact.”  News release and video

In preclinical studies in rats, Dr. Sukumar and colleagues found that the chemotherapy drug doxorubicin could effectively be delivered to the breast this way. When researchers injected the medicine in rats, they found that not only did small tumors of the breast go away, but the rats were protected against future cancers for months. Then, in a phase I trial, Dr. Stearns and colleagues tested the process on three women awaiting mastectomy. First, they injected a sugar solution just to see if it was possible to deliver a substance this way. Then they administered a doxorubicin solution of up to 10 mg, and found a high concentration of drug remained in the breast while very little moved to the rest of the body. By comparison, breast biopsy samples from other women taking doxorubicin intravenously as part of standard care revealed that while high levels of the drug circulated in the body, very little made it to the breast tissues. With intraductal therapy, there were only minimal side effects of some irritation of the nipple or complaints of a feeling of fullness in the breast, that disappeared shortly. Based on these results, Dr. Stearns is designing a larger trial.


Dr. Sara Sukumar, co-director of the Breast Cancer Program, and colleagues are performing a number of studies looking to define the molecular composition of different types of breast cancer, with the long-term goals of developing a blood test for the early detection of breast cancer and developing personalized treatments based on the molecular findings.

Dr. Sukumar currently is working to detect breast cancer DNA in the blood or through tissue biopsies, and understanding the subtypes of breast cancer to tailor treatment, more accurately determining who is likely to benefit from chemotherapy, for example. In 2001, she and her colleagues described in a paper in the Lancet a test that screened for three commonly mutated genes was capable of detecting almost all breast cancers (96 percent) with a high level of specificity and sensitivity. This test accurately detected cancer in two high-risk women who appeared normal through a mammogram. They have gradually expanded the panel to include additional mutated genes.

Her work may make it possible to detect breast cancer from a tiny drop of breast fluid. A test called QM-MSP simultaneously analyzes methylation patterns, a chemical process linked to the silencing of tumor suppressor genes, in five known breast cancer genes. Using the test on a tiny amount of breast fluid (about the size of a pinhead), Dr. Sukumar and colleague Dr. Antonio Wolff found in a study of 64 women that they could detect six of seven cancers using the test. By comparison, just two cancers were identified by microscopic evaluation.

Read an article about Dr. Sukumar’s work from our Breast Center Matters newsletter.

Dr. Lauring and colleagues are building upon the pioneering cancer genetics research completed at the Kimmel Cancer Center that revealed the unique genetic blueprint of breast cancer.  He is studying recurrent genetic alterations in cancer cells, including mutations and large-scale chromosomal changes.  He has identified mutant genes to which certain types of cancer cells become “addicted;” that is, the tumor’s growth and survival is directly tied to these mutant genes. In some cases, these mutant genes are abnormally active and can be successfully targeted with therapy.  A well-known example of this in breast cancer is the Her-2 gene.  Her-2 is over-expressed in about 15 percent of breast cancers and found to play an important role in the progression of the cancer. As a result, a number of active drugs targeting the Her-2 protein have been developed and have dramatically improved survival for this type of breast cancer.  Dr. Lauring is hoping to uncover other targets that may have similar potential for extending survival.

Currently, he is studying mutant genes and chromosomes in human breast cancer cells and cell lines to better understand how the alterations foster abnormal cell growth and the aggressiveness of tumors.  These cell lines will serve as model systems to study drugs or other interventions for their ability to selectively inhibit the growth of breast cancers containing that specific mutant gene. Dr. Lauring and team are currently studying a number of altered genes related to the most common type of breast cancer, known as ER-positive or hormone receptor positive breast cancer. This important research is helping to determine if these mutant genes contribute to sensitivity or resistance to widely used hormonal therapies, such as tamoxifen.

Genomic studies and Targeted Therapies

Ben Ho Park

Dr. Ben Ho Park and colleagues are conducting laboratory studies aimed at discovering and developing novel means for treating breast cancer. The lab is developing techniques to identify genes involved with hormonal and chemotherapeutic drug resistance, as well as analyzing the genes involved in breast cancer initiation and progression.

Using powerful molecular genetic techniques, the lab is identifying genes whose inactivation leads to clinical drug resistance. It has been previously demonstrated that loss of tumor suppressor genes and/or their downstream effectors can confer resistance against certain chemotherapies. The lab hypothesizes that there are other genes whose inactivation can also lead to clinically relevant drug resistance.

Dr. Park's lab also is trying to understand pathogenic mechanisms of growth/hormone receptor signaling. The continuous exposure of breast tissue to estrogens and other growth factors likely plays a role in the cancer-causing process that transforms a normal breast epithelial cell into a cancer. The lab is trying to elucidate the molecular mechanisms of aberrant receptor signaling that contributes to this process.

Recent studies have identified that the PIK3CA gene is the most mutated cancer gene in human breast cancers. Dr. Park and colleagues have identified critical pathways that are activated and lead to growth of breast cancer cells due to these PIK3CA mutations. They are working to identify drugs that specifically target these pathways.


Read Our Blogs
Cancer Matters: timely topics
Our Cancer: for caregivers